VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

C. jejuni FspA1 protein vaccine
Vaccine Information
  • Vaccine Name: C. jejuni FspA1 protein vaccine
  • Target Pathogen: Campylobacter jejuni
  • Target Disease: Campylobacterosis
  • Vaccine Ontology ID: VO_0011485
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: C. jejuni flagellum-secreted protein FspA1
  • fspA1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The fspA1 gene from C. jejuni 81-176 was expressed in Escherichia coli as hexahistidine-tagged proteins in pET-19b. Strains of BL21(DE3) containing each clone were grown in Luria broth containing 100 μg/ml ampicillin and proteins were purified by nickel chromatography under native conditions (Baqar et al., 2008).
    • Detailed Gene Information: Click Here.
  • Adjuvant: LTR192G
  • Immunization Route: Intranasal
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were lightly anesthetized with isoflurane, and 30 μl of phosphate-buffered saline (PBS) alone or PBS containing 5 μg (7 to 10 mice per group) or 25 or 100 μg (10 to 18 mice per group) of protein was applied a drop (5 to 6 μl) at a time to the external nares. A total of three vaccinations for each dose level of each protein were delivered at 2-week intervals. To determine efficacy, animals receiving 100 μg of each protein alone or with 1 μg of LTR192G as the adjuvant were challenged with homologous or heterologous strains of C. jejuni. Following vaccination, animals were observed for two consecutive days for the development of vaccine-associated side effects (Baqar et al., 2008).
  • Challenge Protocol: Twenty-eight days following the last vaccination, mice were intranasally challenged with 3 × 109 CFU of C. jejuni 81-176 or CG8486 (Baqar et al., 2008).
  • Efficacy: Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176 (Baqar et al., 2008).
  • Host IgA response
    • Description: FspA1 induced significantly high levels of fecal IgA in mice 7 days after last vaccination. These results are compared to PBS vaccinated mice (Baqar et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host IgG response
    • Description: FspA1 induced significantly high levels of serum immunoglobulin G (IgG) in mice 18-20 days after 3rd vaccination. These results are compared to PBS vaccinated mice (Baqar et al., 2008).
    • Detailed Gene Information: Click Here.
References
Baqar et al., 2008: Baqar S, Applebee LA, Gilliland TC Jr, Lee LH, Porter CK, Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infection and immunity. 2008; 76(7); 3170-3175. [PubMed: 18426878].